Treatment of STAM NASH mice with the EZH2 inhibitor EPZ-6438 or UNC1999 decreases the mRNA expression of inflammatory cytokines and fibrosis markers [82]. Here, EZH2 is linked to metabolic dysfunction-associated steatohepatitis.